Aarhus University Seal / Aarhus Universitets segl

Pernille Tine Jensen

From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer: Does the revised staging reflect risk groups?

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer : Does the revised staging reflect risk groups? / Sponholtz, Sara Elisabeth; Mogensen, Ole; Hildebrandt, Malene Grubbe; Schledermann, Doris; Parner, Erik; Markauskas, Algirdas; Frøding, Ligita Paskeviciute; Fuglsang, Katrine; Holm, Jorun; Bjørnholt, Sarah Marie; Jensen, Pernille Tine.

I: Gynecologic Oncology, Bind 163, Nr. 2, 11.2021, s. 281-288.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Sponholtz, Sara Elisabeth ; Mogensen, Ole ; Hildebrandt, Malene Grubbe ; Schledermann, Doris ; Parner, Erik ; Markauskas, Algirdas ; Frøding, Ligita Paskeviciute ; Fuglsang, Katrine ; Holm, Jorun ; Bjørnholt, Sarah Marie ; Jensen, Pernille Tine. / From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer : Does the revised staging reflect risk groups?. I: Gynecologic Oncology. 2021 ; Bind 163, Nr. 2. s. 281-288.

Bibtex

@article{50707c9734a9403e96b46434b78b088d,
title = "From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer: Does the revised staging reflect risk groups?",
abstract = "OBJECTIVES: We aimed to evaluate if the revised staging according to FIGO-2018 in early-stage cervical cancer correctly predicts the risk for nodal metastases.METHODS: We reallocated 245 women with early-stage cervical cancer from FIGO-2009 to FIGO-2018 stages using data from a national, prospective cohort study on sentinel lymph node (SLN) mapping. We used univariate and multivariate binary regression models to investigate the association between FIGO-2018 stages, tumor characteristics, and nodal metastases.RESULTS: Stage migration occurred in 54.7% (134/245) (95% CI 48.2-61.0), due to tumor size or depth of invasion (71.6%, 96/134) and nodal metastases (28.4%, 38/134). Imaging preoperatively upstaged 7.3% (18/245); seven had nodal metastatic disease on final pathology. Upstaging occurred in 49.8% (122/245) (95% CI 43.4-56.2%) and downstaging to FIGO-2018 IA stages in 4.9% (12/245) (95% CI 2.6-8.4). The tumor size ranged from 3.0-19.0 mm in women with FIGO-2018 IA tumor characteristics, and none of the 14 women had nodal metastases. In multivariate analysis, risk factors significantly associated with nodal metastases were FIGO-2018 ≥ IB2 (RR 5.01, 95% CI 2.30-10.93, p < 0.001), proportionate depth of invasion >2/3 (RR 1.88, 95% CI 1.05-3.35, p = 0.033), and lymphovascular space invasion (RR 5.56, 95% CI 2.92-10.62, p < 0.001).CONCLUSIONS: The FIGO-2018 revised staging system causes stage migration for a large proportion of women with early-stage cervical cancer. Women who were downstaged to FIGO-2018 IA stages did not have nodal metastatic disease. The attention on depth of invasion rather than horizontal dimension seems to correctly reflect the risk of nodal metastases.",
keywords = "Cervical cancer, FDG-PET/CT imaging, FIGO-2018 staging, Lymph node metastases, Minimally invasive surgery, Sentinel lymph node mapping, FDG-PET, CT imaging, RADICAL HYSTERECTOMY, RANDOMIZED-TRIAL, CARCINOMA, RADIATION-THERAPY",
author = "Sponholtz, {Sara Elisabeth} and Ole Mogensen and Hildebrandt, {Malene Grubbe} and Doris Schledermann and Erik Parner and Algirdas Markauskas and Fr{\o}ding, {Ligita Paskeviciute} and Katrine Fuglsang and Jorun Holm and Bj{\o}rnholt, {Sarah Marie} and Jensen, {Pernille Tine}",
year = "2021",
month = nov,
doi = "10.1016/j.ygyno.2021.08.026",
language = "English",
volume = "163",
pages = "281--288",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "2",

}

RIS

TY - JOUR

T1 - From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer

T2 - Does the revised staging reflect risk groups?

AU - Sponholtz, Sara Elisabeth

AU - Mogensen, Ole

AU - Hildebrandt, Malene Grubbe

AU - Schledermann, Doris

AU - Parner, Erik

AU - Markauskas, Algirdas

AU - Frøding, Ligita Paskeviciute

AU - Fuglsang, Katrine

AU - Holm, Jorun

AU - Bjørnholt, Sarah Marie

AU - Jensen, Pernille Tine

PY - 2021/11

Y1 - 2021/11

N2 - OBJECTIVES: We aimed to evaluate if the revised staging according to FIGO-2018 in early-stage cervical cancer correctly predicts the risk for nodal metastases.METHODS: We reallocated 245 women with early-stage cervical cancer from FIGO-2009 to FIGO-2018 stages using data from a national, prospective cohort study on sentinel lymph node (SLN) mapping. We used univariate and multivariate binary regression models to investigate the association between FIGO-2018 stages, tumor characteristics, and nodal metastases.RESULTS: Stage migration occurred in 54.7% (134/245) (95% CI 48.2-61.0), due to tumor size or depth of invasion (71.6%, 96/134) and nodal metastases (28.4%, 38/134). Imaging preoperatively upstaged 7.3% (18/245); seven had nodal metastatic disease on final pathology. Upstaging occurred in 49.8% (122/245) (95% CI 43.4-56.2%) and downstaging to FIGO-2018 IA stages in 4.9% (12/245) (95% CI 2.6-8.4). The tumor size ranged from 3.0-19.0 mm in women with FIGO-2018 IA tumor characteristics, and none of the 14 women had nodal metastases. In multivariate analysis, risk factors significantly associated with nodal metastases were FIGO-2018 ≥ IB2 (RR 5.01, 95% CI 2.30-10.93, p < 0.001), proportionate depth of invasion >2/3 (RR 1.88, 95% CI 1.05-3.35, p = 0.033), and lymphovascular space invasion (RR 5.56, 95% CI 2.92-10.62, p < 0.001).CONCLUSIONS: The FIGO-2018 revised staging system causes stage migration for a large proportion of women with early-stage cervical cancer. Women who were downstaged to FIGO-2018 IA stages did not have nodal metastatic disease. The attention on depth of invasion rather than horizontal dimension seems to correctly reflect the risk of nodal metastases.

AB - OBJECTIVES: We aimed to evaluate if the revised staging according to FIGO-2018 in early-stage cervical cancer correctly predicts the risk for nodal metastases.METHODS: We reallocated 245 women with early-stage cervical cancer from FIGO-2009 to FIGO-2018 stages using data from a national, prospective cohort study on sentinel lymph node (SLN) mapping. We used univariate and multivariate binary regression models to investigate the association between FIGO-2018 stages, tumor characteristics, and nodal metastases.RESULTS: Stage migration occurred in 54.7% (134/245) (95% CI 48.2-61.0), due to tumor size or depth of invasion (71.6%, 96/134) and nodal metastases (28.4%, 38/134). Imaging preoperatively upstaged 7.3% (18/245); seven had nodal metastatic disease on final pathology. Upstaging occurred in 49.8% (122/245) (95% CI 43.4-56.2%) and downstaging to FIGO-2018 IA stages in 4.9% (12/245) (95% CI 2.6-8.4). The tumor size ranged from 3.0-19.0 mm in women with FIGO-2018 IA tumor characteristics, and none of the 14 women had nodal metastases. In multivariate analysis, risk factors significantly associated with nodal metastases were FIGO-2018 ≥ IB2 (RR 5.01, 95% CI 2.30-10.93, p < 0.001), proportionate depth of invasion >2/3 (RR 1.88, 95% CI 1.05-3.35, p = 0.033), and lymphovascular space invasion (RR 5.56, 95% CI 2.92-10.62, p < 0.001).CONCLUSIONS: The FIGO-2018 revised staging system causes stage migration for a large proportion of women with early-stage cervical cancer. Women who were downstaged to FIGO-2018 IA stages did not have nodal metastatic disease. The attention on depth of invasion rather than horizontal dimension seems to correctly reflect the risk of nodal metastases.

KW - Cervical cancer

KW - FDG-PET/CT imaging

KW - FIGO-2018 staging

KW - Lymph node metastases

KW - Minimally invasive surgery

KW - Sentinel lymph node mapping

KW - FDG-PET

KW - CT imaging

KW - RADICAL HYSTERECTOMY

KW - RANDOMIZED-TRIAL

KW - CARCINOMA

KW - RADIATION-THERAPY

U2 - 10.1016/j.ygyno.2021.08.026

DO - 10.1016/j.ygyno.2021.08.026

M3 - Journal article

C2 - 34503847

VL - 163

SP - 281

EP - 288

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -